GeneTex
United States (US)

Myeloperoxidase antibody

Cat No. GTX29535

Host Rabbit
Clonality Polyclonal
Isotype IgG
Application ICC/IF, IHC-P, IHC-Fr
Reactivity Human, Rat
APPLICATION

Application Note

This antibody may be diluted to a titer of 1:25-1:100 in an ABC method. We suggest an incubation period of 30-60 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation and dilutions should be determined by the user.

Calculated MW

84 kDa. ( Note )

Positive Control

Tonsil or Spleen tissue sections

Specificity/Sensitivity

This antibody reacts with human myeloperoxidase. It stains granules of neutrophils granulocytes in spleen, bone marrow, tonsil and blood smears.
PROPERTIES

Form

Liquid

Buffer

PBS pH7.5 containing 1%BSA and 0.05% sodium azide

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.

Concentration

0.5mg/ml(Please refer to the vial label for the specific concentration.)

Antigen Species

Human

Immunogen

Myeloperoxidase isolated from human granulocytes

Purification

Protein A purified

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Cellular Localization

Lysosomal

Background

Myeloperoxidase is a hemoprotein that is abundantly expressed in neutrophils and secreted during their activation. Native Myeloperoxidase is represented as a covalently bound tetrameric complex of two glycosylated alpha chains (MW 59 - 64 kDa) and two unglycosylated beta chains (MW 14 kDa) with total MW 150 kDa and theoretical pI 9.2. Traditionally Myeloperoxidase was considered as a main target of anti-neutrophil cytoplasm antibodies (ANCA), the serological markers for certain systemic vasculities e.g. periarteriitis nodosa, microscopic polyarteriitis and pulmonary eosinophilic granulomatosis (Churg-Strauss syndrome). Low to moderate anti-Myeloperoxidase autoantibody levels are also reported in rheumatoid arthritis. Recently it was shown that Myeloperoxidase participates in the initiation and progression of cardiovascular disease. It possesses potent proinflammatory properties and may contribute directly to tissue injury. Now Myeloperoxidase is under consideration as one of the most promising cardiac markers.

Database

Research Area

Package List Price ($)
$ 319